2023
Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening
Cartmel B, Fucito L, Bold K, Neveu S, Li F, Rojewski A, Gueorguieva R, O'Malley S, Herbst R, Toll B. Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening. Journal Of Thoracic Oncology 2023, 19: 643-649. PMID: 37977486, PMCID: PMC10999350, DOI: 10.1016/j.jtho.2023.11.012.Peer-Reviewed Original ResearchStandard of careLung cancer screeningCancer screeningQuit ratesGain-framed messagingPack-year smoking historySmoking cessation ratesSmoking quit ratesNumber of cigarettesTobacco treatment interventionsYears of ageCessation/reductionChi-square testSelf-reported numberSmoking historyStandard careCessation ratesRandomized trialsTobacco treatmentTobacco cessationBiomarker feedbackLung cancerSmoking abstinencePost randomizationSmoking behavior
2022
P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial
Dercle L, Gomez D, Zhao B, Kelly K, Herbst R, Redman M, Gandara D, Schwartz L. P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial. Journal Of Thoracic Oncology 2022, 17: s152. DOI: 10.1016/j.jtho.2022.07.251.Peer-Reviewed Original Research
2006
A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer
Herbst R, Mendolson D, Ebbinghaus S, Gordon M, O’Dwyer P, Lieberman G, Ing J, Kurzrock R, Novotny W, Eckhardt G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Journal Of Clinical Oncology 2006, 24: 3013-3013. DOI: 10.1200/jco.2006.24.18_suppl.3013.Peer-Reviewed Original ResearchAdvanced solid tumorsLiver metastasesSolid tumorsHematologic malignanciesApo2L/TRAILRecombinant human Apo2L/TRAILPost-baseline tumour assessmentPhase I safetyObjective partial responseFurther dose optimizationAttributable toxicityStable diseaseAdult patientsI safetyPartial responseAdvanced cancerCommon diagnosisRandomized trialsStandard treatmentReceptor agonistOvarian cancerPreclinical modelsSafety dataTumor assessmentMost normal cells
2001
Emerging therapies in non-small-cell lung cancer
Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Annals Of Oncology 2001, 12: 739-744. PMID: 11484947, DOI: 10.1023/a:1011197500223.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCancer-related deathFive-year survival rateRole of chemotherapyMultiple randomized trialsAdvanced diseaseStage IADevastating causeMetastatic diseaseModality therapyOnly patientsRandomized trialsStage IVSurvival rateNew casesCancerChemotherapyTherapyDiseaseDeathPatientsYear 2000Trials